Phase 2 Leukaemia Trial, Recruiting NCT06904482 Sponsor: Case Comprehensive Cancer Center Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06904482
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with one of the following blood cancers: high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), a bone marrow disorder called myelodysplastic syndrome (MDS) that is intermediate to very high risk, or high-risk lymphoma.
  • Your leukemia or blood cancer is currently in remission (meaning the cancer is not detectable or is under control) at the required stage as determined by your doctor.
  • You are 18 years of age or older.
  • You do not have a closely matched stem cell donor available (either a family member or unrelated donor).
  • You have access to a suitable stem cell source — either a cord blood unit or a "half-matched" (haploidentical) donor — that meets specific cell count requirements (confirm with trial site).
  • If you have had cancer affecting your brain or spinal fluid in the past, it must be in remission at the time you enroll.
  • You are able to understand the study and are willing to sign a written consent form.

Who may not be able to join:

  • Your kidneys, liver, lungs, or heart are not functioning well enough, based on specific blood tests and other measurements (confirm with trial site).
  • You have a serious uncontrolled illness, such as an active infection, uncontrolled heart problems, or a mental health or personal situation that would make it difficult to follow the study requirements.
  • You are currently pregnant or breastfeeding, because the chemotherapy used in this trial could be harmful to a baby.
  • You have any other condition that, in your doctor's opinion, would make it unsafe for you to participate or would affect the results of the study.
  • You have a known allergy or bad reaction to any of the medications used in this trial.
  • You have had a stem cell transplant using your own cells or a CAR-T cell therapy in the past 6 months, or you have ever had a stem cell transplant using someone else's cells.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Leland Metheny, MD, Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center

Phone: 216-844-0139

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
13 August 2025
Est. completion
24 February 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Progression free survival(PFS) at 6 months after transplant

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov